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Fecal microbiota transplantation (FMT) is a widely accepted alternative therapy for Clos-
tridioides difficile infection and other gastrointestinal disorders. Thorough donor screening 
is required as a safety control measure to minimize transmission of infectious agents in 
FMT. We report the donor screening process and outcomes at a fecal microbiota bank in 
Korea. From August 2017 to June 2020, the qualification of 62 individuals as FMT donors 
was evaluated using clinical assessment and laboratory tests. Forty-six (74%) candidates 
were excluded after clinical assessment; high body mass index (>25) was the most com-
mon reason for exclusion, followed by atopy, asthma, and allergy history. Four of the re-
maining 16 (25%) candidates failed to meet laboratory test criteria, resulting in a 19% 
qualification rate. FMT donor re-qualification was conducted monthly as an additional 
safety control measure, and only three (5%) candidates were eligible for repeated dona-
tion. As high prevalence of multidrug-resistant organisms (55%) and Helicobacter pylori 
(44%) were detected in qualified donors during the screening, a urea breath test was 
added to the existing protocol. The present results emphasize the importance of imple-
menting a donor re-qualification system to minimize risk factors not identified during initial 
donor screening.
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Fecal microbiota transplantation (FMT) is widely used as a last 
resort treatment for Clostridioides difficile infection; it has also 
been demonstrated to be an effective treatment for other gastro-
intestinal disorders [1-3]. The increasing demand for FMT has 
led to the establishment of several fecal microbiota banks 
around the world to provide safe access to donor feces. Several 
reports have outlined FMT donor-screening criteria for minimiz-
ing the risk of infectious agent transmission [4-10]. A recent re-
port on serious adverse effects associated with extended spec-
trum β-lactamase (ESBL)-producing Enterobacteriaceae trans-
mission via FMT emphasizes the need for rigorous FMT donor 
screening [11]. Implementation of a standardized FMT donor 
screening protocol is important; however, some modifications to 
the protocol may be required when considering the local preva-
lence of infectious agents [8].
Many European and North American fecal microbiota banks 
have recently reported their donor screening outcomes, and 
these data have provided insights for establishing evidence-
based FMT consensus reports [4-10, 12]. However, there is a 
paucity of such reports from Asian fecal microbiota banks, de-
spite there being numerous publications on FMT clinical out-
comes [13, 14]. This report presents the donor screening out-




Seo HS, et al.
FMT donor screening in Korea
https://doi.org/10.3343/alm.2021.41.4.424 www.annlabmed.org  425
In November 2016, Microbiotix Corporation, a university hos-
pital-affiliated startup company, founded a non-profit fecal mi-
crobiota bank in collaboration with physicians from various disci-
plines (laboratory medicine, gastroenterology, pulmonology, and 
infectious disease). This fecal microbiota banking project was 
approved by the Severance Hospital Institutional Review Board, 
Seoul, Korea (IRB No. 4-2016-0850). Donors were recruited 
through poster advertisements at the Yonsei University Health 
System starting August 2017. Individuals interested in fecal do-
nation were invited for a two-stage donor-screening process 
(stage 1, clinical assessment; stage 2, laboratory tests) created 
based on the Korean Transfusion Guidelines and the European 
and American FMT donor screening protocols [4, 5, 9, 15]. 
A summary of the donor screening criteria is provided in Table 
1. All donor candidates provided informed consent to partici-
pate in the study. An in-person clinical assessment (stage 1) 
was carried out to evaluate the donor candidates for general 
health and gastrointestinal conditions and for any risk factors for 
transmissible diseases. This process was performed by a nurse 
clinical research coordinator and was verified by a laboratory 
medicine specialist. At stage 2, donor candidates underwent 
serological/fecal screening, a urea breath test (UBT), and chest 
(posteroanterior) radiography to identify underlying health con-
ditions and potentially transmissible pathogens. Although FMT 
is recognized as a safe and effective treatment with manageable 
adverse effects (e.g., bloating, cramping, and diarrhea), it is 
crucial to acknowledge previously reported adverse effects pos-
sibly associated with FMT [16, 17]. A previous study reported 
two cases of FMT-associated ESBL-producing Escherichia coli 
bacteremia in the United States, which led the US Food and 
Drug Administration to mandate additional screening against 
multidrug-resistant organisms (MDRO) [16]. Therefore, we rig-
orously screened for viral, bacterial, and protozoal pathogens to 
prevent potential pathogen transmission via FMT.
The qualification of 62 candidates to serve as potential FMT 
donors was assessed from August 2017 through June 2020 
(Fig. 1). Forty-six (74%) candidates were excluded based on 
the pre-screening questionnaire responses. High body mass in-
dex (BMI; >25) was the most common reason for donor exclu-
sion (16 individuals), followed by atopy, asthma, and allergy his-
tory (15 individuals). The remaining 16 candidates underwent 
serological/fecal screening, and four (25%) failed to meet labo-
ratory test criteria. Of the donor candidates excluded at stage 2, 
three candidates (75%) had abnormal blood test results and 
one carried ESBL-producing Enterobacteriaceae. Overall, 12 
candidates (19% of the initial donor candidate pool) qualified as 
FMT donors. Our study outcome was consistent with the donor 
qualification rates in earlier reports [6, 7, 9].
All fecal material from the qualified donors was processed into 
slurries and quarantined for one month to ensure that it passed 
the monthly re-qualification process. The re-qualification pro-
cess involved the same clinical assessment and laboratory test 
stages as the initial screening process. After the re-qualification 
process, nine candidates (75%) did not meet the laboratory test 
criteria as they showed risks for infectious diseases (five with 
MDRO, four with Helicobacter pylori, one with enteric bacteria, 
and one with Blastocystis hominis colonization; one candidate 
had a positive UBT result) (Fig. 1). Finally, only three candidates 
(5% of the donor candidate pool) were eligible to donate feces. 
These results suggest that continuous donor recruitment is nec-
essary to prevent a shortage of donors and FMT materials. Ear-
lier reports demonstrated similar donor-screening outcomes, 
with several candidate donors failing to meet the re-qualification 
criteria [6, 9]. A high percentage of donor failure on monthly re-
qualification screening of FMT donors emphasizes that such 
screening could prevent the potential transmission of infectious 
materials through FMT by identifying risk factors not detected in 
the initial screening process.
Regular screening of FMT donors is crucial, as it serves as an 
ongoing safety control measure. H. pylori carriage was not a 
concern for donor candidate disqualification during the initial 
donor screening. However, four of the initially qualified donors, 
accounting for 33% of the qualified donors, were excluded ow-
ing to H. pylori carriage during the re-qualification process. Ow-
ing to the high prevalence of potentially asymptomatic H. pylori 
carriers in the donor pool, our center added UBT to the ongoing 
screening process in May 2019. Although nested PCR for H. 
pylori detection was used due to its high sensitivity and specific-
ity, possible degradation of H. pylori DNA may have contributed 
to a lower rate of positive test results [18]. UBT, the gold stan-
dard for H. pylori diagnosis, was added to the existing donor 
screening protocol as an additional method for identifying as-
ymptomatic H. pylori carriers [18-20]. A larger sample size may 
be required to obtain a better representation of the healthy pop-
ulation in Korea and determine whether high H. pylori preva-
lence could be a generalizable criterion for donor exclusion in 
Asian fecal microbiota banks.
To the best of our knowledge, this is the first report to outline 
the donor screening process and outcomes at a fecal microbiota 
bank in Asia. After establishing donor screening criteria based 
on pre-existing protocols and consensus reports, the FMT donor 
qualification rate was 19%. High BMI (>25; N=16) and abnor-
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mal serological test results (increased total bilirubin level (2.2 
mg/dL) and positive antinuclear antibody test; N=4) were the 
major criteria for donor exclusion based on clinical assessment 
and laboratory tests, respectively. A monthly donor re-qualifica-
tion process contributed to a high overall donor exclusion rate. 
It resulted in identifying new risk factors, including carriage of 
infectious agents (H. pylori and B. hominis) and abnormal li-
pase and amylase levels, that were not considered during the 
initial donor screening process for FMT.
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